Shifts in endocrine homeostasis and preventive hormone replacement therapy: extending the Women’s Health Initiative globally
© The Author(s) 2016
Received: 22 March 2016
Accepted: 18 July 2016
Published: 30 July 2016
Reducing disease risk for women after menopause is global health issue. A major portion of the Women’s Health Initiative (WHI) consisted of two clinical trials involving 161,809 post-menopausal women aged 50–79 that tested the effect of hormone replacement therapy (HRT) on reducing cardiovascular disease and other secondary outcomes. Previous analyses of the data reveal that HRT should not be recommended for post-menopausal women, but show potential benefits for younger women. Thus, there may be a critical period just prior to or during the early stages of menopause where HRT could be both safe and beneficial.
Menopause marks the beginning of a process of non-reversible reduction in estrogen by which estrogen levels decline progressively, followed by a reduction in estrogen receptors. This results in periods of hormone-receptor imbalances, exacerbating the effects of lower serum estrogen and is considered the primarily endocrinal source of menopause symptoms. Eventually a hormone-receptor balance is achieved at a lower level.
Here, we purport that the negative outcomes from WHI trials were primarily due to the fact preventive HRT was initiated in women who had already achieved hormone-receptor equilibrium at lower hormonal levels.
We argue for further HRT clinical trials in women at varying stages of menopause, including pre-menopause and early menopause, and in women from different countries. Variation across countries and subgroups in how women experience menopause and perceive menopause symptoms suggest that biocultural differences should be considered in both study design and measurement approaches to test the effectiveness of HRT. Particularly, we recommend longitudinal studies to assess changes in hormonal level over time, and to detect the “most effective period” for HRT to reduce health risk for women going through the whole menopause period.
KeywordsHormone replacement therapy Menopause Dynamic endocrine changes Women’s health
Reducing disease risk for women after menopause is global health issue. A group of leading scientists from a number of universities in the United States launched the program Women’s Health Initiative (WHI) in 1991 with funding primarily from the U.S. National Institutes of Health. A major portion of WHI consists of two clinical trials involving 161,809 post-menopausal women aged 50–79 from 40 clinics. The two trials tested the effect of hormone replacement therapy (HRT) on reducing cardiovascular disease (CVD), with invasive breast cancer (IBC), hip fracture, stroke, and more as secondary outcomes (e.g. [4, 9, 10]). The trials were halted due to observed consistent increases in CVD and IBC risks .
More recently, Manson and colleagues performed an age-stratified analysis of the WHI data, including additional years of follow-up and concluded that, similar to previous analyses, HRT should not be recommended for chronic disease prevention in post-menopausal women [4, 5, 9]. However, Manson’s analysis reveals benefits to an estrogen-only regimen for younger women (e.g., those aged 50–59), suggesting there may be a critical period just prior to or during the early stages of menopause to initiate preventive HRT. Similar critical period hypotheses have been examined with respect to HRT and Alzheimer’s disease (e.g. [6, 7]), and with HRT and cognition and mood  with varying results.
These studies were conducted in post-menopausal Caucasian women in the United States, rather than women from multiple countries and ethnic backgrounds that are in pre- and early-menopause. We argue that the critical window theory should be further examined in geographically and culturally diverse women cohorts who in multiple stages of menopause and for other health outcomes in a global setting before dismissing HRT as dangerous in all postmenopausal women.
Menopause marks the beginning of a process of non-reversible reduction in estrogen. According to the , during the approximately one-year of menopausal transition, estrogen levels decline progressively, followed by a reduction in estrogen receptors. This results in periods of hormone-receptor imbalances, exacerbating the effects of lower serum estrogen and is considered the primarily endocrinal source of menopause symptoms. The subsequent alleviation of the menopause symptoms during the early menopause period (3–4 years) indicates a new, hormone-receptor equilibrium was reached at low hormonal levels, which is associated with an increased risk of CVD. The rationale of the WHI trials was to supply estrogen with an expectation to curb this risk of CVD .
The negative outcomes from WHI trials were primarily due to the fact preventive HRT was initiated in women who had already achieved hormone-receptor equilibrium at lower hormonal levels . Hormonal therapy at this period will disturb the established balance. Endocrinologically, it would be more favorable if hormone therapy were to be initiated during the premenopausal transition period when the new hormone-receptor equilibrium at the low hormonal levels has not yet been established . Appropriate levels of estrogen supplementation during this period would minimize periods of hormone-receptor imbalance and would thus allow women to proceed through the menopausal transition at a slower pace, lessening menopause symptoms and reducing other health risks, including cardiovascular disease .
Furthermore, globally, women’s hormonal levels and the changes in those levels during menopause can vary widely between countries. Similarly, how women experience menopause and perceive menopause symptoms suggest that biocultural differences should be considered when selecting both study design and measurement approaches to test the effectiveness of HRT . Particularly, we recommend longitudinal studies to assess changes in hormonal level over time, and to detect the “most effective period” for HRT to reduce health risk for women going through the whole menopause period.
There is significant need for additional longitudinal studies like the WHI in multiple international contexts to test this hypothesis by recruiting and following women in different countries based on their stage of menopause, and to tease out confounding from lifestyle, cultural and genetic variation. Through these studies, we could devise appropriate HRT dosage and timing recommendations based on existing knowledge of hormone and receptor decline following menopause using a time-since-menopause analysis , and design the trials to address the variable health concerns of the multiple populations that are represented. While it might be technically and practically challenging to identify and recruit women in menopausal transition stage for research purpose, the criterion for menopause transition established by  provide a solid foundation for developing valid measurement tools to address this challenge. Appropriately timed HRT has the potential to not only alleviate menopause symptoms, but also to reduce risk of CVD, IBC and other negative health outcomes across the globe.
JDB and XC conceived the study, participated in its design, and helped draft the manuscript. Both authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- American Society for Reproductive Medicine Committee Opinion. The menopausal transition. Fertil Steril. 2008;90 Suppl 3:S61–5.Google Scholar
- Gleason CR, Dowling NM, Wharton W, Manson JE, Miller VM, et al. Effects of hormone therapy on cognition and mood in recently postmenopausal women: Findings from the randomized controlled KEEPS—Cognitive and Affective study. PLoS Med. 2015. doi:https://doi.org/10.1371/journal.pmed.1001833.PubMedPubMed CentralGoogle Scholar
- Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Women’s Health. 2006;15(1):35–44.View ArticleGoogle Scholar
- Hsia J, Langer RD, Manson JE, et al. Conjugated Equine Estrogens and Coronary Heart Disease: The Women’s Health Initiative. Arch Intern Med. 2006;166(3):357–65. doi:https://doi.org/10.1001/archinte.166.3.357.View ArticlePubMedGoogle Scholar
- Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA. 2013;310(13):1353–68.View ArticlePubMedGoogle Scholar
- Marder K, Sano M. Estrogen to treat Alzheimer’s disease: Too little, too late? So what’s a woman to do? Neurology. 2000;54(11):2035–7.View ArticlePubMedGoogle Scholar
- Marder K, Tang MX, Alfaro B, Mejia H, Cote L, Jacobs D, et al. Postmenopausal estrogen use and Parkinson’s disease with and without dementia. Neurology. 1998;50(4):1141–3.View ArticlePubMedGoogle Scholar
- Obermeyer CM. Menopause across cultures: a review of the evidence. Menopause. 2000;7(3):184–92.View ArticlePubMedGoogle Scholar
- Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–33.View ArticlePubMedGoogle Scholar
- Wassertheil-Smoller S, Hendrix S, Limacher M, et al. Effect of Estrogen Plus Progestin on Stroke in postmenopausal Women: The Women’s Health Initiative: A Randomized trial. JAMA. 2003;289(20):2673–84. doi:https://doi.org/10.1001/jama.289.20.2673.View ArticlePubMedGoogle Scholar